|
Title
|
|
|
|
Gold compounds as cysteine protease inhibitors : perspectives for pharmaceutical application as antiparasitic agents
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Gold compounds form a new class of promising metal-based drugs with a number of potential therapeutic applications, particularly in the fields of anticancer and antimicrobial treatments. Previous research revealed that a group of structurally diverse gold compounds cause conspicuous inhibition of the protease activities of the human proteasome. Given the pharmacological importance of protease inhibition, the present study further explored whether these gold compounds might inhibit a few other proteases that are accepted druggable targets for disease treatment. In particular, four distinct cysteine proteases were considered here: cathepsin B and L that play a primary role in tumor-cell invasion and metastasis; rhodesain, the major cathepsin L-like cysteine protease of Trypanosoma brucei rhodesiense and CPB2.8 Delta CTE, a Leishmania mexicana mature cysteine protease. Based on the encouraging results obtained for some of the tested gold compounds on the two parasitic cysteine proteases, especially against CPB2.8 Delta CTE, with IC50s in the micromolar range, we next evaluated whether those gold compounds might contrast effectively the growth of the respective protozoa and indeed important antiprotozoal properties were disclosed; on the other hand a certain lack of selectivity was highlighted. Also, no direct or clear correlation could be established between the in vitro antiprotozoal properties and the level of protease inhibition. The implications of these results are discussed in relation to possible pharmaceutical applications. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Biometals. - Oxford
| |
|
Publication
|
|
|
|
Oxford
:
2017
| |
|
ISSN
|
|
|
|
0966-0844
| |
|
DOI
|
|
|
|
10.1007/S10534-017-0007-0
| |
|
Volume/pages
|
|
|
|
30
:2
(2017)
, p. 313-320
| |
|
ISI
|
|
|
|
000398709100015
| |
|
Pubmed ID
|
|
|
|
28283781
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|